[ad_1]
Good news on the vaccine front. The pharmaceutical company AstraZeneca predicts that the Covid-19 test vaccine will be in an “advanced phase of distribution by the end of the first quarter of next year.” Explained it Josep Baselga, director of cancer research and development at AstraZeneca, in an interview with Catalan radio ‘Rac1’. Again, according to Baselga, there will be “three billion doses of the vaccine that I am sure will be effective.”
📌 Dr. Josep Baselga: “Between November and the end of the year there will already be more than one vaccine available” @ elmonarac1 https://t.co/IyRDkZ4XvC
– RAC1 (@ rac1) November 2, 2020
Therefore, the advanced distribution of the Covid vaccine could take place from March 2021.. “We start producing millions and millions of doses of vaccines before we know if it works because we don’t want to wait six months. At the beginning of the year we will already have three billion doses ”, explained the Catalan doctor. Baselga also specified that the vaccine will be sold at a cost, around two euros and that two doses will be required 28 days apart.
AstraZeneca’s Executive Vice President of the Oncology Research and Development Department recalled that “the company is committed to the distribution of vaccines worldwide and not just in individual states or in Europe.” As for the current situation, “it will be a harsh winter and we cannot think of going back to life as before.”
According to Baselga, currently “175 different vaccines are being worked on around the world, 35 of which are in clinical trials with patients and 10 in their final testing phase.” “The vaccine will help, but it is not the only solution,” he warns, asking for caution. And indeed, Baselga points out that AstraZeneca is also developing ‘a treatment with monoclonal antibodies».
Also, experimentation is going well. “I can say that at present everything is going in the best way and there is no evidence to suggest contraindications from the point of view of age and pathologies,” he tells Radio Cusano Campus. Piero Di Lorenzo, President and CEO of Irbm Pomezia, with respect to the Oxford-Irbm-AstraZeneca anti-Covid vaccine candidate. As for the Financial Times’ indiscretion regarding the robust immune response in older people, “this is an indiscretion because, it points out, nothing has yet been published on phase three. I would avoid commenting on rumors.
Covid vaccine: age, ethnicity and weight, these are the priorities according to doctors
Covid, the miracle of Taiwan (23 million inhabitants): “For 200 days no positive without closures or curfews”
Covid Vaccine, Abhinav (12 years old) is the smallest volunteer in the world to undergo the test: “This is how I help research”
Last updated: 16:14
© REPRODUCTION RESERVED
[ad_2]
